Skip to main content
Clinical Trials/NCT06611228
NCT06611228
Recruiting
Not Applicable

Optimizing Prevention of Hospital-acquired Disability Through Integrated Multidomain Interventions: the Age-IT Project

University of Milano Bicocca1 site in 1 country288 target enrollmentDecember 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Frailty Syndrome
Sponsor
University of Milano Bicocca
Enrollment
288
Locations
1
Primary Endpoint
Evaluate the feasibility of home-based MDI with technological support
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The aim of this study is to assess whether a multidomain, multidisciplinary intervention (MDI), enhanced by technological solutions, effectively improves the functional and cognitive status of older hospitalized patients at risk of disability or worsening frailty. Additionally, the study will evaluate the feasibility and acceptability of delivering these interventions remotely via technology after hospital discharge.

Participants will:

  • Receive an MDI during their hospital stay and continue with remote at-home support for 3 months, or receive usual care.
  • Attend outpatient clinics for follow-up assessment at 3 and 6 months.

Detailed Description

The "Optimizing Prevention of Hospital-Acquired Disability Through Integrated Multidomain Interventions (OPTIMAge-IT)" study will evaluate impact of a MDI multidisciplinary approach, enhanced by technological solutions, on the functional and cognitive status of older hospitalized patients at risk of disability or worsening frailty. Additionally, the study will evaluate the feasibility and acceptability of delivering MDIs remotely via technology after hospital discharge. Using a parallel cluster-randomized design, approximately 300 patients will be recruited from eight Acute Geriatric Units (AGUs) located in eight acute hospitals evenly distributed across Northern, Central, and Southern Italy. Eligible patients will be aged 70 years or older, with mild to moderate frailty, capable of ambulation with or without assistance and able to communicate and collaborate with the research team. Participants will use smart technologies, such as smartwatches, and tablets, for guided physical activity and remote monitoring. A multidisciplinary team -including a geriatrician, a nurse, a physiotherapist, a clinical nutrition expert, a neuropsychologist and a digital coach- will assist patients in the intervention group, supervising the MDI approach during hospitalization and at the 3-month follow-up. Blood-based biomarkers and fecal samples for gut microbiome analysis will be collected for patients in the intervention group, to support frailty stratification at baseline and help define the trajectories of functional and cognitive changes from baseline to follow-up assessments. After discharge, patients in the intervention group will continue MDI at home for 12 weeks, with follow-up visits at 3 and 6 months. The control group will receive a follow-up visit at 6 months.

Registry
clinicaltrials.gov
Start Date
December 1, 2024
End Date
January 1, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \>70 years;
  • Mild to moderate frailty, defined by a panel of tools agreed upon by the group of researchers involved in the study (Primary Care Frailty Index \[PC-FI\] between 0.07 and 0.21, Clinical Frailty Scale \[CFS\] 4-6);
  • Ability to walk with or without assistance
  • Ability to communicate and cooperate with the research team;
  • Ability to sign informed consent.

Exclusion Criteria

  • Expected hospital stay duration \<3 days;
  • Estimated prognosis quoad vitam \<12 months;
  • Persistent clinical instability, indicated by a NEWS2 score \>5 (assessed within 48 hours of admission) and/or the presence of delirium (4AT \>4);
  • History of schizophrenia, major depression, bipolar disorder, or psychosis;
  • Severe sensory deficits (visual and auditory);
  • Presence of a nasogastric tube or percutaneous endoscopic gastrostomy (PEG);
  • Severe cardiac conduction disorder (e.g., third-degree atrioventricular block), uncontrolled arrhythmia, new Q wave in the past six months, or ST segment depression (\>3 mm) on the electrocardiogram;
  • Terminal stage oncological or organic disease (e.g., Child-Pugh C cirrhosis, stage V renal disease, GOLD stage D chronic obstructive pulmonary disease, end-stage heart failure);
  • Residence in a nursing home before hospital admission;
  • Presence of dissected aortic aneurysm, severe aortic stenosis, acute endocarditis/pericarditis, acute thromboembolism, uncontrolled hypertension (\>180/100 mmHg) or postural hypotension, uncontrolled hypoglycemia, recent fracture within the last month, or any other medical condition that hinders the execution of physical activity according to clinical judgment;

Outcomes

Primary Outcomes

Evaluate the feasibility of home-based MDI with technological support

Time Frame: 3 months, and 6 months

Feasibility of home-based MDI with technological support, evaluated using Patient Reported Experience Measures (PREMs), questionnaires measuring the patients' perceptions of their experience whilst receiving care

Evaluate the participant adherence to the protocol

Time Frame: through study completion, an average of 1 year

Evaluate the participant adherence to the protocol assessing the number of drop-out and overall retention rates

Assess the effect of the MDI on motor function at discharge from the AGU

Time Frame: Baseline, Discharge (after an average hospital stay of 10 days)

Effect of the intervention in terms of motor function, assessed using the Short Physical Performance Battery (SPPB, from 0 to 12)

Secondary Outcomes

  • Assess the effect of the MDI on readmissions at 6 months follow-up.(6 months)
  • Assess the effect of the MDI on readmissions at 3 months follow-up.(3 months)
  • Evaluate the effect of the MDI on quality of life at follow-up.(3 months, 6 months)
  • Evaluate the effect of the MDI on in-hospital mortality(From Admission Through Discharge, an Average of 10 days)
  • Evaluate the effect of the MDI on mortality at follow-up.(3 months, 6 months)
  • Evaluate the effect of the MDI on dietary intake and nutritional status at follow-up.(Baseline, 3 months, 6 months)
  • Evaluate the effect of the MDI on changes in frailty levels at follow-up.(Baseline, 3 months, 6 months)
  • Assess the effect of the MDI on fall events(Baseline, From Admission Through Discharge, an Average of 10 days, 3 months, 6 months)
  • Evaluate the effect of the MDI on in-hospital complications(Baseline, From Admission Through Discharge, an Average of 10 days, 3 months, 6 months)
  • Assess the effect of the MDI on sleep quality(Baseline, From Admission Through Discharge, an Average of 10 days, 3 months, 6 months)
  • Assess the effect of the MDI on the incidence of delirium during hospitalization(From Admission Through Discharge, an Average of 10 days)
  • Assess the effect of the MDI on cognitive performance at follow-up.(Baseline, From Admission Through Discharge, an Average of 10 days, 3 months, 6 months)
  • Assess the effect of the MDI on functional performance at follow-up(Baseline, From Admission Through Discharge, an Average of 10 days, 3 months, 6 months)
  • Assess the effect of the MDI on motor performance at follow-up.(Baseline, From Admission Through Discharge, an Average of 10 days, 3 months, 6 months)
  • Assess the acceptability of technological solutions during hospitalization and at follow-up.(Discharge (after an average hospital stay of 10 days), 3 months, and 6 months)
  • Evaluate the cost impact of the MDI on the healthcare system.(Discharge (after an average hospital stay of 10 days), 3 months, and 6 months)
  • Evaluate the effect of the MDI on the length of hospital stay.(Discharge (after an average hospital stay of 10 days))

Study Sites (1)

Loading locations...

Similar Trials